Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission

Gray zone lymphoma (GZL) is a rare type of B-cell lymphoma characterized by features of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma (cHL). The prognosis of GZL is poorer than that of cHL and mediastinal large B-cell lymphoma. However, an optimal treatment strategy for relapsed/...

Descripción completa

Detalles Bibliográficos
Autores principales: Terao, Toshiki, Yuda, Junichiro, Yamauchi, Nobuhiko, Guo, Yong-Mei, Shimada, Kaoru, Sugano, Masato, Ishii, Genichiro, Minami, Yosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082227/
https://www.ncbi.nlm.nih.gov/pubmed/33936598
http://dx.doi.org/10.3892/mco.2021.2287
_version_ 1783685809085349888
author Terao, Toshiki
Yuda, Junichiro
Yamauchi, Nobuhiko
Guo, Yong-Mei
Shimada, Kaoru
Sugano, Masato
Ishii, Genichiro
Minami, Yosuke
author_facet Terao, Toshiki
Yuda, Junichiro
Yamauchi, Nobuhiko
Guo, Yong-Mei
Shimada, Kaoru
Sugano, Masato
Ishii, Genichiro
Minami, Yosuke
author_sort Terao, Toshiki
collection PubMed
description Gray zone lymphoma (GZL) is a rare type of B-cell lymphoma characterized by features of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma (cHL). The prognosis of GZL is poorer than that of cHL and mediastinal large B-cell lymphoma. However, an optimal treatment strategy for relapsed/refractory (R/R) GZL has not been established in the clinical setting. The current study reported an excellent clinical response in a patient with R/R CD30-positive GZL who received brentuximab vedotin (BV) maintenance after autologous stem cell transplantation (ASCT). Although the patient was resistant to prior treatments, BV maintenance after ASCT achieved long-term remission. Hence, BV was determined to be a safe and effective therapeutic option for CD30-positive R/R GZL.
format Online
Article
Text
id pubmed-8082227
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-80822272021-04-30 Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission Terao, Toshiki Yuda, Junichiro Yamauchi, Nobuhiko Guo, Yong-Mei Shimada, Kaoru Sugano, Masato Ishii, Genichiro Minami, Yosuke Mol Clin Oncol Articles Gray zone lymphoma (GZL) is a rare type of B-cell lymphoma characterized by features of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma (cHL). The prognosis of GZL is poorer than that of cHL and mediastinal large B-cell lymphoma. However, an optimal treatment strategy for relapsed/refractory (R/R) GZL has not been established in the clinical setting. The current study reported an excellent clinical response in a patient with R/R CD30-positive GZL who received brentuximab vedotin (BV) maintenance after autologous stem cell transplantation (ASCT). Although the patient was resistant to prior treatments, BV maintenance after ASCT achieved long-term remission. Hence, BV was determined to be a safe and effective therapeutic option for CD30-positive R/R GZL. D.A. Spandidos 2021-06 2021-04-23 /pmc/articles/PMC8082227/ /pubmed/33936598 http://dx.doi.org/10.3892/mco.2021.2287 Text en Copyright: © Terao et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Terao, Toshiki
Yuda, Junichiro
Yamauchi, Nobuhiko
Guo, Yong-Mei
Shimada, Kaoru
Sugano, Masato
Ishii, Genichiro
Minami, Yosuke
Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission
title Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission
title_full Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission
title_fullStr Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission
title_full_unstemmed Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission
title_short Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission
title_sort brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082227/
https://www.ncbi.nlm.nih.gov/pubmed/33936598
http://dx.doi.org/10.3892/mco.2021.2287
work_keys_str_mv AT teraotoshiki brentuximabvedotinmaintenanceafterautologousstemcelltransplantationforrefractorygrayzonelymphomawithlongtermremission
AT yudajunichiro brentuximabvedotinmaintenanceafterautologousstemcelltransplantationforrefractorygrayzonelymphomawithlongtermremission
AT yamauchinobuhiko brentuximabvedotinmaintenanceafterautologousstemcelltransplantationforrefractorygrayzonelymphomawithlongtermremission
AT guoyongmei brentuximabvedotinmaintenanceafterautologousstemcelltransplantationforrefractorygrayzonelymphomawithlongtermremission
AT shimadakaoru brentuximabvedotinmaintenanceafterautologousstemcelltransplantationforrefractorygrayzonelymphomawithlongtermremission
AT suganomasato brentuximabvedotinmaintenanceafterautologousstemcelltransplantationforrefractorygrayzonelymphomawithlongtermremission
AT ishiigenichiro brentuximabvedotinmaintenanceafterautologousstemcelltransplantationforrefractorygrayzonelymphomawithlongtermremission
AT minamiyosuke brentuximabvedotinmaintenanceafterautologousstemcelltransplantationforrefractorygrayzonelymphomawithlongtermremission

Ejemplares similares